Hansoh Pharmaceutical Group Full Year 2024 Earnings: Beats Expectations

Hansoh Pharmaceutical Group (HKG:3692) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥12.3b (up 21% from FY 2023).
• Net income: CN¥4.37b (up 33% from FY 2023).
• Profit margin: 36% (up from 32% in FY 2023). The increase in margin was driven by higher revenue.
• EPS: CN¥0.74 (up from CN¥0.55 in FY 2023).

We check all companies for important risks. See what we found for Hansoh Pharmaceutical Group in our free report.

3692 Post-Clinical Trial Products

• Launched (during full year): 7.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hansoh Pharmaceutical Group Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 3.3%.

In the last 12 months, the only revenue segment was Sales of Pharmaceutical Products contributing CN¥12.3b. The largest operating expense was Sales & Marketing costs, amounting to CN¥3.80b (52% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥469.7m. Explore how 3692's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 2.1% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Hansoh Pharmaceutical Group's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.